Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease. Journal of diabetes and its complications Chertow, G. M., Appel, G. B., Block, G. A., Chin, M. P., Coyne, D. W., Goldsberry, A., Kalantar-Zadeh, K., Meyer, C. J., Molitch, M. E., Pergola, P. E., Raskin, P., Silva, A. L., Spinowitz, B., Sprague, S. M., Rossing, P. 2018


AIMS: Obesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.METHODS: Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to <30?mL/min/1.73?m2) were randomized 1:1 to receive once-daily oral dose of bardoxolone methyl (20?mg) or placebo.RESULTS: BEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7?kg; 95% CI: -6.0 to -5.3?kg; p?

View details for PubMedID 30318163